Royal Palms Capital LLC Makes New $3.55 Million Investment in Teva Pharmaceutical Industries Ltd. $TEVA

Royal Palms Capital LLC bought a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the 4th quarter, HoldingsChannel.com reports. The fund bought 113,857 shares of the company’s stock, valued at approximately $3,553,000. Teva Pharmaceutical Industries accounts for about 4.2% of Royal Palms Capital LLC’s portfolio, making the stock its 9th biggest holding.

Several other large investors also recently bought and sold shares of the stock. Harel Insurance Investments & Financial Services Ltd. grew its position in Teva Pharmaceutical Industries by 19.2% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock worth $1,402,945,000 after purchasing an additional 7,255,083 shares during the last quarter. Phoenix Financial Ltd. grew its position in Teva Pharmaceutical Industries by 9.4% during the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock worth $834,164,000 after purchasing an additional 3,533,800 shares during the last quarter. Menora Mivtachim Holdings LTD. grew its position in Teva Pharmaceutical Industries by 1.1% during the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company’s stock worth $786,190,000 after purchasing an additional 427,000 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its position in Teva Pharmaceutical Industries by 14.8% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company’s stock worth $1,167,323,000 after purchasing an additional 4,820,000 shares during the last quarter. Finally, Rubric Capital Management LP grew its position in Teva Pharmaceutical Industries by 1.8% during the 2nd quarter. Rubric Capital Management LP now owns 26,000,000 shares of the company’s stock worth $435,760,000 after purchasing an additional 450,000 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insider Activity

In related news, insider Mark Sabag sold 144,180 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $34.99, for a total transaction of $5,044,858.20. Following the sale, the insider directly owned 80,760 shares of the company’s stock, valued at approximately $2,825,792.40. This represents a 64.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Richard Daniell sold 30,000 shares of the stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the sale, the executive vice president directly owned 55,755 shares in the company, valued at $1,973,727. This trade represents a 34.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 1,280,269 shares of company stock valued at $42,755,980 in the last three months. Corporate insiders own 0.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on TEVA shares. UBS Group upped their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Piper Sandler reiterated an “overweight” rating and issued a $42.00 price objective (up from $41.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, April 30th. Bank of America increased their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, April 9th. JPMorgan Chase & Co. increased their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, April 20th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.78.

Teva Pharmaceutical Industries Stock Up 1.7%

NYSE:TEVA opened at $34.66 on Wednesday. The firm has a market capitalization of $39.85 billion, a P/E ratio of 26.06, a PEG ratio of 3.29 and a beta of 0.86. Teva Pharmaceutical Industries Ltd. has a 1-year low of $14.99 and a 1-year high of $37.35. The company’s fifty day moving average price is $32.05 and its 200-day moving average price is $31.16. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The firm had revenue of $3.98 billion for the quarter. As a group, equities research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.49 EPS for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.